Key result
Simvastatin, but not fenofibrate, lowered C-reactive protein by 32% on day 3 and reduced platelet activation, while both drugs showed early antithrombotic and anti-inflammatory effects.
Why the study?
Does simvastatin compared to fenofibrate improve markers of inflammation, thrombin formation, and platelet activation in patients with hypercholesterolemia at high risk of CAD?
RCT (n=42)
Double-blind
randomized
Does simvastatin compared to fenofibrate improve markers of inflammation, thrombin formation, and platelet activation in patients with hypercholesterolemia at high risk of CAD?
Statins and fibrates exert rapid anti-inflammatory and antithrombotic effects within 3 days of therapy, but only statins appear to inhibit platelet function early on.
Answers are grounded in this paper and cite their sources.
Simvastatin may be preferred over fenofibrate for rapid CRP and platelet effects in high-risk hypercholesterolemia; extends evidence for early differential pleiotropic actions.
Summary The aim of the study was to determine whether a short-term treatment with simvastatin or fenofibrate may result in beneficial anti-inflammatory and antithrombotic effects in patients with high risk of coronary artery disease. In a randomized, double-blind study, we compared markers of inflammation, thrombin formation and platelet activation in patients with LDL cholesterol >130 mg/dl assigned to receive simvastatin (40 mg/d; n=20) or micronised fenofibrate (160 mg/d; n=22) for 28 days. Simvastatin, but not fenofibrate, lowered C-reactive protein (CRP) by 32% on day 3 (p<0.001), while both drugs reduced CRP significantly on day 28. Interleukin-6, soluble CD40 ligand, and monocyte chemoattractant protein-1 levels decreased significantly (by 20 to 50%) in both treatment groups on days 3 and 28. Soluble cell adhesion molecules remained unchanged in both groups. Simvastatin and fenofibrate significantly lowered plasma concentrations of thrombin-antithrombin complexes on days and 28, but not platelet β-thromboglobulin (βTG) levels. Soluble P-selectin was lowered only in the simvastatin group. The total amount of thrombin generated at the site of microvascular injury also declined (by about 30%) as early as after 3 days of fenofibrate or simvastatin therapy, whereas βTG release was reduced only in the simvastatin group on days 3 and 28.All the effects were independent of the changes in lipid profiles. Our results suggest that statins and fibrates can exert antithrombotic and anti-inflammatory effects as early as after 3 days of therapy. However, in contrast to statins, fibrates have no influence on platelet function within one month of therapy.
No takes yet. Share an insight, caveat, or question.
Undas et al. (2005) conducted an RCT in Hypercholesterolemia (n=42). Simvastatin vs. Micronised fenofibrate (160 mg/d) was evaluated on C-reactive protein (CRP) reduction on day 3 (p=<0.001). Simvastatin, but not fenofibrate, lowered C-reactive protein by 32% on day 3 and reduced platelet activation, while both drugs showed early antithrombotic and anti-inflammatory effects.
Synapse has enriched 10 related papers. Consider them for comparative context: